Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model.

Villarreal DO, Svoronos N, Wise MC, Shedlock DJ, Morrow MP, Conejo-Garcia JR, Weiner DB.

Vaccine. 2015 Aug 20;33(35):4313-20. doi: 10.1016/j.vaccine.2015.03.086. Epub 2015 Apr 14.

2.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

3.

Gammaherpesvirus latency differentially impacts the generation of primary versus secondary memory CD8+ T cells during subsequent infection.

Barton ES, Rajkarnikar S, Langston PK, Price MJ, Grayson JM.

J Virol. 2014 Nov;88(21):12740-51. doi: 10.1128/JVI.02106-14. Epub 2014 Aug 20.

4.

Alarmin IL-33 elicits potent TB-specific cell-mediated responses.

Villarreal DO, Siefert RJ, Weiner DB.

Hum Vaccin Immunother. 2015;11(8):1954-60. doi: 10.1080/21645515.2015.1026499.

5.

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD.

Nat Med. 2010 Mar;16(3):339-45. doi: 10.1038/nm.2104. Epub 2010 Feb 7.

6.

Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB.

Cancer Res. 2014 Mar 15;74(6):1789-800. doi: 10.1158/0008-5472.CAN-13-2729. Epub 2014 Jan 21.

7.

Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.

Tan X, Sande JL, Pufnock JS, Blattman JN, Greenberg PD.

J Virol. 2011 Aug;85(16):8316-27. doi: 10.1128/JVI.00781-11. Epub 2011 Jun 8.

8.

Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes.

Takagi A, Matsui M, Ohno S, Duan H, Moriya O, Kobayashi N, Oda H, Mori M, Kobayashi A, Taneichi M, Uchida T, Akatsuka T.

Clin Vaccine Immunol. 2009 Oct;16(10):1383-92. doi: 10.1128/CVI.00116-09. Epub 2009 Aug 12.

9.

Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.

Jackson RJ, Worley M, Trivedi S, Ranasinghe C.

Vaccine. 2014 Sep 29;32(43):5703-14. doi: 10.1016/j.vaccine.2014.08.023. Epub 2014 Aug 20.

10.

Modulation of SIV and HIV DNA vaccine immunity by Fas-FasL signaling.

Yan J, Zapata JC, Pauza CD, Salvato MS.

Viruses. 2015 Mar 23;7(3):1429-53. doi: 10.3390/v7031429.

11.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.

12.

A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses.

Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postól E, Kalil J, Cunha-Neto E.

PLoS One. 2011 Feb 11;6(2):e16921. doi: 10.1371/journal.pone.0016921.

13.

A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, Mallilankaraman K, Cisper NJ, Morrow MP, Wu SJ, Kawalekar OU, Khan AS, Sardesai NY, Muthumani K, Shen H, Weiner DB.

Vaccine. 2011 Sep 9;29(39):6755-62. doi: 10.1016/j.vaccine.2010.12.064. Epub 2011 Jan 14.

14.

Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.

Holechek SA, McAfee MS, Nieves LM, Guzman VP, Manhas K, Fouts T, Bagley K, Blattman JN.

Vaccine. 2016 Nov 4;34(46):5629-5635. doi: 10.1016/j.vaccine.2016.09.013. Epub 2016 Sep 23.

15.

The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus.

Kotturi MF, Peters B, Buendia-Laysa F Jr, Sidney J, Oseroff C, Botten J, Grey H, Buchmeier MJ, Sette A.

J Virol. 2007 May;81(10):4928-40. Epub 2007 Feb 28.

16.

Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice.

Grujic M, Holst PJ, Christensen JP, Thomsen AR.

J Gen Virol. 2009 Feb;90(Pt 2):414-22. doi: 10.1099/vir.0.002105-0.

PMID:
19141451
18.

Hydrodynamic immunization leads to poor CD8 T-cell expansion, low frequency of memory CTLs and ineffective antiviral protection.

Obeng-Adjei N, Choo DK, Weiner DB.

Cancer Gene Ther. 2013 Oct;20(10):552-63. doi: 10.1038/cgt.2013.52. Epub 2013 Aug 23.

19.

A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.

Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Kotturi MF, Sette A, Buchmeier MJ.

J Virol. 2010 Oct;84(19):9947-56. doi: 10.1128/JVI.00672-10. Epub 2010 Jul 28.

20.

CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+ T Cell Responses.

Kanuma T, Yamamoto T, Kobiyama K, Moriishi E, Masuta Y, Kusakabe T, Ozasa K, Kuroda E, Jounai N, Ishii KJ.

J Immunol. 2017 Jun 15;198(12):4707-4715. doi: 10.4049/jimmunol.1600731. Epub 2017 May 15.

Supplemental Content

Support Center